Avid Bioservices (NASDAQ: CDMO) reported Q4 EPS of ($0.04), versus ($0.11) reported last year. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $21.6 million.

GUIDANCE:

Avid Bioservices sees FY2021 revenue of $115-117 million, versus the consensus of $89.9 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.